IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishRifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS.
Laterza, L., Ianiro, G., Scoleri, I., Landi, R., Scaldaferri, F., Gaetani, E., Campanale, M., Gasbarrini, A., Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome, <<EXPERT OPINION ON PHARMACOTHERAPY>>, 2015; 16 (4): 607-615. [doi:10.1517/14656566.2015.1007951] [http://hdl.handle.net/10807/68311]
| Autori: | |
| Titolo: | Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1517/14656566.2015.1007951 |
| Data di pubblicazione: | 2015 |
| Abstract: | Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics, in particular, rifaximin, has been demonstrated to improve IBS symptoms in non-constipation subtypes of IBS. |
| Lingua: | Inglese |
| Rivista: | |
| Citazione: | Laterza, L., Ianiro, G., Scoleri, I., Landi, R., Scaldaferri, F., Gaetani, E., Campanale, M., Gasbarrini, A., Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome, <<EXPERT OPINION ON PHARMACOTHERAPY>>, 2015; 16 (4): 607-615. [doi:10.1517/14656566.2015.1007951] [http://hdl.handle.net/10807/68311] |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
Copyright © 2020